HDAC Inhibitors Market Demand 2020 – Size, Share, Key Trends, Technology, Comprehensive Analysis, Healthcare Infrastructure, Business Opportunities, Challenges and Highest Growth Rate During Forecast Period 2026
SEATTLE, March 17, 2021, (PHARMIWEB) — HDAC inhibitors are a class of anti-cancer agents that play a crucial role in non-epigenetic or epigenetic regulation, inducing cell cycle arrest, apoptosis, and death of cancer cells. Histone deacetylase inhibitors (HDACi) are emerging therapeutics, which have already promising sign in oncological applications such as cancer detection, diagnosis, and prognosis. For instance, Merck & Co. Inc.’s Vorinostat is a novel drug used in the management of cutaneous T-cell lymphoma during disease progression or relapse or while undergoing treatment. Current candidates have shown successful pre-clinical and clinical trials for various other diseases such as neurological ailments, heart diseases, and HIV infections.
Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1294
There are various classes of Histone deacetylase inhibitors present including benzamides such as MS-275, organic hydroxamic acids such as TSA and SAHA, cyclic tetrapeptides such as sulfonamide anilides and trapoxin, and short-chain fatty acids such as valproic acid and butyrates. Growing adoption of HDAC inhibitors in different therapeutic areas such as neurodegenerative diseases, including Huntington’s and Alzheimer’s disease, Polycythemia vera, inflammation, and essential Thrombocythemia, Myelofibrosis, is expected to fuel the demand for HDAC inhibitors in the near future.
Increasing R&D activities for cancer is expected to boost global HDAC inhibitors market growth during the forecast period
In February 2015, Novartis received the U.S. Food and Drug Administration (FDA) approval for Farydak capsules along with dexamethasone and bortezomib for patients suffering from multiple myeloma, who have previously received minimum two regimens. Moreover, increasing research and development activities for the treatment of cancer and other neurological disorders is another factor driving growth of the global HDAC inhibitors market. Around 350 clinical trials were conducted or are under process using HDACi as single therapeutic or along with other targeted agents against different human diseases. However, uncertainty issues about the therapeutic potential of HDAC inhibitors and strict compensation policies is expected to hamper growth of the market in near future. For instance, there can be significant delays in gaining reimbursement and coverage for newly approved drugs by the U.S. FDA or other foreign regulatory authorities.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Quick Buy – HDAC Inhibitors Market Research Report: https://bit.ly/2QfvB4H
Market Taxonomy
On the basis of application, the global HDAC inhibitors market is segmented into:
- Oncology
- Neurology
- Other
On the basis of end-user, the global HDAC inhibitors market is segmented into:
- Hospitals
- Oncology Clinics
- Other
North America is expected to hold a dominant position in the global HDAC inhibitors market, owing to growing demand for cancer therapeutics in the region
Regional segmentation of HDAC inhibitors market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among regions, North America is expected to hold a dominant position in the market during the forecast period. This is owing to growing incidence of cancer and increasing demand for cancer therapeutics in the region. According to the American Cancer Society, in 2017, 1,688,780 new cancer cases and 600,920 deaths caused due to cancer in the U.S. Moreover, increased funding for R&D for cancer treatment coupled with increasing demand for efficient treatment with lower costs are also expected to drive growth of the global HDAC inhibitors market in the future. For instance, in 2017, the U.S. Congress approved the 21st Century Cures Act, sanctioning US$ 1.8 billion in funding for the Cancer Moonshot initiative for 7 years. Moreover, Europe is expected to witness significant growth during the forecast period (2017–2025). This is owing to growing presence of robust healthcare infrastructure, early adoption of innovative therapeutics, and increasing expenditure on research and development activities.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/hdac-inhibitors-market-1294
Increasing collaborations for R&D among pharmaceutical companies is expected to boost the market growth
Key players in the market are focused on various growth strategies such research and development to introduce novel products. For instance, in January 2018, Syndax and Genentech extended their study of the effects of combining PD-L1 and HDAC inhibitors. This new contract permits Genentech to test its Tecentriq with Syndax’s entinostat in a subset of breast cancer patients.
Major players operating in the global HDAC inhibitors market include AbbVie, Celgene, Celldex, Chipscreen, Chroma Therapeutics, GSK, Merck, Novartis, Onxeo, Syndax, and Spectrum Pharmaceuticals.
Need a discount?
Note: *The discount is offered on the Standard Price of the report.
Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/1294
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Application
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- PEST Analysis
- Market Dynamics
- Global HDAC Inhibitors – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Safety Syringes for COIVD-19 Vaccines
- Global HDAC Inhibitors Market, By Product Type, 2016 – 2027, (US$ Mn)
- Global HDAC Inhibitors Market, By Application, 2016 – 2027, (US$ Mn)
- Global HDAC Inhibitors Market, By End User, 2016 – 2027, (US$ Mn)
- Global HDAC Inhibitors Market, By Region, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
